[1] Berger K, Kurth T. RLS Epidemiology — Frequencies, Risk Factors and Methods in Population Studies. Mov Disord 2007; 22 Suppl 18: S420–3

[2] DGN Leitlinien Restless-Legs-Syndrom (RLS) und Periodic Limb Movement Disorder (PLMD) 2012

[3] Allen RP, Picchietti D, Hening WA et al. Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology – a report from the restless legs syndrome diagnosis and epidemiology workshop at the NIH. Sleep Med 2003; 4: 101–119

[4] Benes H, Kohnen R. Validation of an algorithm for the diagnosis of restless legs syndrome: the restless legs syndrome-diagnostic index (RLS-DI). Sleep Med 2009; 10: 515–523

[5] Trenkwalder C, Canelo M, Lang M et al. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Med. 2017; 30: 257–265

[6] Fachinformation Leganto, Stand x.x.xxxx

[7] Dohin E, Högl B, Ferini-Strambi L et al. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years. Expert Opin Pharmacother 2013; 14(1): 15–25

[8] Oertel WH, Benes H, Garcia-Borreguero D et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008; 9: 228–239

[9] Trenkwalder C, Benes H, Poewe W et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebocontrolled trial. Lancet Neurol 2008; 7: 595–604

[10] Stiasny-Kolster K, Berg D, Hofmann WE et al. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany. Sleep Med 2013; 14: 475–481